1. Design and Development of a Series of Potent and Selective Type II Inhibitors of CDK8
   Philippe Bergeron et al, 2016, ACS Med. Chem. Lett. CrossRef
2. Assessing the mechanism and therapeutic potential of modulators of the human Mediator complex-associated protein kinases
   Paul A Clarke et al, 2016 CrossRef
3. Development of a Potent, Specific CDK8 Kinase Inhibitor Which Phenocopies CDK8/19 Knockout Cells
   Michael F. T. Koehler et al, 2016, ACS Med. Chem. Lett. CrossRef
4. Cyclin-Dependent Kinase 8: A New Hope in Targeted Cancer Therapy?
   Stephen Philip et al, 2018, J. Med. Chem. CrossRef
5. Retroviral Cyclin Controls Cyclin-Dependent Kinase 8-Mediated Transcription Elongation and Reinitiation
   Claire H. Birkenheuer et al, 2015, J. Virol. CrossRef
6. CDK8/19 inhibition induces premature G1/S transition and ATR-dependent cell death in prostate cancer cells.
   Akito Nakamura et al, 0 CrossRef
7. NK Cell–Specific CDK8 Deletion Enhances Antitumor Responses
   Agnieszka Witalisz-Siepracka et al, 2018, Cancer Immunol Res CrossRef
8. Insights into the regulatory role and clinical relevance of mediator subunit, MED12, in human diseases.
   Srishti Srivastava et al, 2021, J Cell Physiol CrossRef
9. Exploration of Potential Cyclin-dependent Kinases and their Inhibitors to Combat Abnormal Signalling and Cancer
   Pradeep Pilania et al, 2024, CST CrossRef
10. Targeting super-enhancer activity for colorectal cancer therapy
    Ioannis A Voutsadakis, 2024, Am J Transl Res CrossRef